Obesity, defined as BMI greater than 30 kg/m², affects over one billion people globally and drives a substantial proportion of type 2 diabetes, cardiovascular disease, and certain cancers. GLP-1 receptor agonists, particularly semaglutide and tirzepatide, have achieved unprecedented weight loss efficacy, fundamentally reshaping the treatment paradigm. Long-term outcomes, equitable access, and managing the anticipated treatment demand are the defining challenges ahead.
Setmelanotide curbs insatiable hunger in acquired hypothalamic obesity
Setmelanotide significantly improved body mass index, hunger, and hyperphagia symptoms in patients with acquired hypothalamic obesity, according to the TRANSCEND trial.
Your obesity patients deserve more than just weight loss goals
Modern obesity treatment is shifting focus from simple weight loss to more meaningful clinical endpoints, reflecting a broader understanding of the disease's impact.
Why lifestyle advice alone still dominates obesity searches
Despite advances in pharmacotherapy, Google searches for obesity management remain heavily skewed towards lifestyle interventions, indicating a persistent public perception.
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Metabolic syndrome, affecting one in four adults, significantly accelerates brain aging and increases the risk of cognitive decline, impacting neurovascular health.
Weight-Loss Jabs May Create a New Kind of Yo-Yo Dieting
GLP-1 receptor agonists, while effective for weight reduction, present a significant risk of weight regain upon cessation, challenging long-term management strategies.
Obesity as Disease: Who Benefits from the Redefinition?
Classifying obesity as a disease shifts focus from lifestyle to medical intervention, benefiting pharmaceutical companies and specific patient subgroups.
Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity
A targeted therapy effectively reversed weight gain in patients with a rare genetic form of obesity, demonstrating significant reductions in body weight.
Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
Erling Haaland's reported 6,000-calorie daily diet, while fueling elite athletic performance, presents significant long-term health considerations for the general population.
Why are weight-loss drugs now heart drugs too?
New evidence confirms weight-loss drugs improve cardiovascular outcomes and quality of life in patients with overweight or obesity.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12